Double-Blind, Placebo-Controlled, Randomized, Parallel-Group Study in Subjects With Relapsing Forms of Multiple Sclerosis to Evaluate the Effects of Different CDP323 Doses on Biomarker Patterns as Well as on Safety and Tolerability.
Phase of Trial: Phase I/II
Latest Information Update: 04 Jun 2015
At a glance
- Drugs CDP 323 (Primary)
- Indications Multiple sclerosis
- Focus Pharmacodynamics
- Sponsors UCB
- 11 Mar 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 11 Mar 2009 Actual end date (Mar 2009) added as reported by ClinicalTrials.gov.
- 20 Aug 2008 New trial record.